PMID

Data

Article Title

Organization

Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist.

Zydus Research Centre

Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.

Chinese Academy of Sciences

4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists.

Chinese Academy of Sciences

Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.

Genomics Institute of The Novartis Research Foundation

Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold.

Chinese Academy of Sciences

Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.

F. Hoffmann-La Roche

Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.

Pfizer

Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists.

Chinese Academy of Sciences

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.

Kalypsys